L
L. Lupinacci
Researcher at Hospital Italiano de Buenos Aires
Publications - 23
Citations - 1850
L. Lupinacci is an academic researcher from Hospital Italiano de Buenos Aires. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 6, co-authored 16 publications receiving 876 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D. Hellmann,Luis Paz-Ares,Reyes Bernabe Caro,B. Zurawski,Sang-We Kim,Enric Carcereny Costa,Keunchil Park,A. Alexandru,L. Lupinacci,Emmanuel de la Mora Jimenez,Hiroshi Sakai,Istvan Albert,Alain Vergnenegre,Solange Peters,Konstantinos N. Syrigos,Fabrice Barlesi,Martin Reck,Hossein Borghaei,Julie R. Brahmer,Kenneth J. O'Byrne,William J. Geese,Prabhu Bhagavatheeswaran,Sridhar K. Rabindran,Ravi S. Kasinathan,F. E. Nathan,Suresh S. Ramalingam +25 more
TL;DR: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level.
Journal ArticleDOI
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis Paz-Ares,Suresh S. Ramalingam,Tudor-Eliade Ciuleanu,Jong Seok Lee,László Urbán,Reyes Bernabe Caro,Keunchil Park,Hiroshi Sakai,Yuichiro Ohe,Makoto Nishio,Clarisse Audigier-Valette,Jacobus A. Burgers,Adam Pluzanski,Randeep Sangha,Carlos Gallardo,Masayuki Takeda,Helena Linardou,L. Lupinacci,Ki Hyeong Lee,Claudia Caserta,Mariano Provencio,Enric Carcereny,Gregory A. Otterson,Michael Schenker,B. Zurawski,A. Alexandru,A. Vergnenegre,Judith Raimbourg,Kynan Feeney,Sang-We Kim,Hossein Borghaei,Kenneth J. O'Byrne,Matthew D. Hellmann,Arteid Memaj,F. E. Nathan,Judith Bushong,Phuong Tran,Julie R. Brahmer,Martin Reck +38 more
TL;DR: For example, CheckMate 227 as discussed by the authors showed that nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% or less than 1% (prespecified descriptive analysis).
Journal ArticleDOI
Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
Solange Peters,S.S. Ramalingam,Luis Paz-Ares,R. Bernabe Caro,B. Zurawski,Sang We Kim,A. Alexandru,L. Lupinacci,E. De La Mora Jimenez,Hiroshi Sakai,Istvan Albert,A. Vergnenegre,Martin Reck,Hossein Borghaei,Julie R. Brahmer,Kenneth J. O'Byrne,William J. Geese,Prabhu Bhagavatheeswaran,F. E. Nathan,Matthew D. Hellmann +19 more
TL;DR: CheckMate 227 met its primary endpoint of significantly improved OS with NIVO + IPI vs chemo in 1L advanced NSCLC with PD-L1 ≥ 1%, and OS was also improved with N IVO +IPI in PD- L1 Clinical trial identification NCT02477826.
Journal ArticleDOI
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
Alejandro Ruiz-Patiño,Oscar Arrieta,Andrés F. Cardona,Claudio Martin,Luis E. Raez,Z. Zatarain-Barrón,Feliciano Barrón,Luisa Ricaurte,María A. Bravo‐Garzón,Luis Mas,Luis Corrales,Leonardo Rojas,L. Lupinacci,F. Perazzo,Carlos Bas,Omar Carranza,Carmen Puparelli,Manglio Miguel Rizzo,Rossana Ruiz,Christian Rolfo,Pilar Archila,July Rodriguez,C. Sotelo,Carlos Vargas,Hernán Carranza,Jorge Otero,Luis Eduardo Pino,Carlos Ortiz,Paola Laguado,Rafael Rosell +29 more
TL;DR: Patients with advanced or metastatic non‐small cell lung cancer who received immunotherapy as first‐, second‐ or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors are compared.
Journal ArticleDOI
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Mariona Riudavets,Edouard Auclin,Miguel Mosteiro,Naomi Dempsey,Margarita Majem,Riccardo Lobefaro,R. López-Castro,Joaquim Bosch-Barrera,Sara Pilotto,Elena Escalera,Marco Tagliamento,Joaquín Mosquera,Gérard Zalcman,Frank Aboubakar Nana,Santiago Ponce,Alessandro Dal Maso,M. Spotti,X. Mielgo-Rubio,Elodie Mussat,Roxana Reyes,Jose Carlos Benitez,L. Lupinacci,Boris Duchemann,Andrea De Giglio,Juan Bautista Blaquier,Clarisse Audigier-Valette,Matthias Scheffler,Ernest Nadal,Gilberto Lopes,Diego Signorelli,Rosario García-Campelo,Jessica Menis,V. Bluthgen,Marc Campayo,Gonzalo Recondo,Benjamin Besse,David Planchard,Laura Mezquita +37 more
TL;DR: Durvalumab is the standard-of-care as consolidation therapy after chemo-radiotherapy in stage III unresectable non-small cell lung cancer (NSCLC); however, its activity across patients with NASC harboring driver genomic alterations (dGA) is poorly characterised as discussed by the authors .